Asparlas
(Calaspargase Pegol-mknl)Phase 1Small molecule
This medication is an enzyme used alongside other chemotherapy drugs to treat acute lymphocytic leukemia (a blood cancer) in young patients. It works by blocking essential nutrients that cancer cells need to grow, thereby killing cancer cells or stopping their growth.[1] Asparlas is currently being investigated across 1 indication[3], with its most advanced program in Phase 1.[1]
Asparlas is one of 53 small molecule programs targeting Acute Myeloid Leukemia. It is currently in Phase 1.
1
Indications
4
Total Trials
2
Active Trials
52
Competitors
5
FDA Applications
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
235 competitors in Acute Myeloid Leukemia
#DrugCompanyPhaseTrials
1Idamycin
PfizerPhase 3
Xospata
AstellasPhase 3
Vepesid
AAvyxa
Phase 3
Mylotarg
WWyeth-Lederle Vaccines
Phase 3
Cerubidine
HHikma Pharmaceuticals LLC
Phase 3
Neupogen
EEastern Cooperative Oncology Group
Phase 3
Nexavar
BayerPhase 3
Cellcept
RochePhase 3
Cytoxan
BBaxter Healthcare Corporation
Phase 3
Novantrone
EMD SeronoPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Acute Lymphoblastic Leukemia1 trial
T-cell acute lymphoblastic leukemia1 trial
Regulatory
FDA Approval Timeline[4]
Dec 20, 2018
ASPARLAS
NDA BLA761102
Sep 5, 2019
ASPARLAS
NDA BLA761102
Jun 24, 2020
ASPARLAS
NDA BLA761102
Dec 21, 2021
ASPARLAS
NDA BLA761102
Nov 29, 2023
ASPARLAS
NDA BLA761102
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Calaspargase Pegol-mknl. EMBL-EBI & Wellcome Sanger Institute.
- [4]
- [5]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 1[1]
- Company
- MM.D. Anderson Cancer Center